Newsfilter article unlocker

Samantha Semenkow
Vice President

I'm Sam Semenkow, one of the biotech analysts here at Citi, and it's my pleasure to be hosting Voyager Therapeutics. I'm joined by Al Sandrock, President and CEO; Nate Jorgensen, CFO; Todd Carter, CSO; and Trista Morrison, Chief of Communications. Thank you all for being here today. So I'm actually going to turn it over to you, Al. I think you have a couple of slides you want to run through.

Alfred Sandrock
President, CEO & Director

Great. We have some forward-looking statements on this slide. So what's the investment rationale for Voyager? We would summarize it on this slide here. We have an exciting pipeline of neuro assets. We expect 4 programs in the clinic in 2026. And one of those programs, VY7523, we expect data in the second half of next year, which is our anti-tau antibody in a fairly decent-sized multiple ascending dose study, where we'll look at the effects of our antibody on the spread of pathological tau in Alzheimer's patients.

And among those programs, we have 4 wholly owned programs in Alzheimer's disease, including the most recent entry, which is APOE. We have programs targeting amyloid as well as tau and APOE. Neuro has been considered risky by the industry and our strategy to mitigate the risk in neuro is based on several factors. One is we focus on validated targets, targets validated predominantly by human genetics. We take programs forward where we think we can derisk early in the clinic, where we think we can get human